Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: Where did surveillance fail

American Journal of Gastroenterology

Volumn 108, Issue 3, 2013, Pages 425-432

  Singal, Amit G ^a,b,c   Nehra, Mahendra ^a   Adams Huet, Beverley ^a,b   Yopp, Adam C ^a   Tiro, Jasmin A ^b   Marrero, Jorge A ^a   Lok, Anna S ^d   Lee, William M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER STAGING; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT DURATION;

AGED; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 84875229858     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.449     Document Type: Article

References (25)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
2. Singal AG, Marrero JA. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 2010; 26: 189-95.
3. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7.
4. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2010; 53: 1-35.
6. Singal A, Volk ML, Waljee A et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
7. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
8. Zapka JG, Taplin SH, Solberg LI et al. A framework for improving the quality of cancer care: The case of breast and cervical cancer screening. Cancer Epidemiol Biomarkers Prev 2003; 12: 4-13.
9. Leyden WA, Manos MM, Geiger AM et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 2005; 97: 675-83.
10. Taplin SH, Ichikawa L, Yood MU et al. Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? J Natl Cancer Inst 2004; 96: 1518-27.
11. Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastro Hep 2013 (in-press).
12. Davila JA, Henderson L, Kramer JR et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis c virus-infected veterans in the united states. Ann Intern Med 2011; 154: 85-93.
13. Davila JA, Morgan RO, Richardson PA et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the united states. Hepatology 2010; 52: 132-41.
14. Singal A, Volk M, Rakoski M et al. Patient involvement is correlated with higher hcc surveillance in patients with cirrhosis. J Clin Gastroenterol 2011; 45: 727-32.
15. Singal AG, Yopp A, Skinner C et al. Utilization of hepatocellular carcinoma surveillance among american patients: a systematic review. J Gen Intern Med Jan 4; 2012: 861-7.
16. Mant J. Process vs. outcome indicators in the assessment of quality of health care. Int J Qual Health Care 2001; 13: 475-80.
17. Di Bisceglie AM, Shiff man M, Everson GT. Prolonged therapy of advanced chronic hepatitis c with low-dose peginterferon. N Engl J Med 2008; 359: 2429-41.
18. Lok AS, Everhart JE, Wright EC et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis c. Gastroenterology 2011; 140: 840-49; quiz-e812.
19. Lok AS, Sterling RK, Everhart JE et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
21. Bremner KE, Bayoumi AM, Sherman M et al. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007; 21: 491-500.
22. Kubota K, Ina H, Okada Y et al. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci 2003; 48: 581-6.
23. Singal AG, Yopp A, Gupta S et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res 2012; 5: 1124-30.
24. Singal AG, Conjeevaram HS, Volk ML et al. Effectiveness of hepato cellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012; 21: 793-9.
25. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis 2005; 9: 235-51, vi.